Therefore, the beneficial role of HLA-E*0101 for avoiding relapse of CML could be related to its decreased expression on the cell surface, which could result in lower inhibitory activity of NKG2A+ cells [70], and to a less restrictive peptide repertoire presentation than that found with HLA-E*0103 [71]. The gene discussed is KLRC1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.